News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Spain’s Zeltia SA Jumps on Ovarian Cancer Drug News
August 7, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MADRID, Aug 7 (Reuters) - Spanish pharmaceutical firm Zeltia said on Thursday it would seek regulatory approval for the use of its Yondelis drug to treat ovarian cancer after good results from final trials, sending the stock soaring.
Twitter
LinkedIn
Facebook
Email
Print
Regulatory
Europe
MORE ON THIS TOPIC
FDA
FDA Demurs on GLP-1 Compounding Fight, Debuts Consumer ‘Green List’ Instead
September 8, 2025
·
2 min read
·
Annalee Armstrong
Lung cancer
Summit’s Keytruda Challenger Hits Cross-Country Consistency Problems, Raising US Approval Questions
September 8, 2025
·
2 min read
·
Tristan Manalac
GLP-1
WHO Adds GLP-1s to List of Essential Medicines
September 8, 2025
·
2 min read
·
Tristan Manalac
Government
Monarez Blasts Partisan Public Health Policy at CDC Under RFK Jr.
September 5, 2025
·
2 min read
·
Tristan Manalac
